AMRI Announces Review of its Hungary Operation
News Jan 24, 2012
AMRI has announced that as part of its ongoing global operations review to improve efficiency and customer service, it is considering a restructuring of its European operations focused on a reduction of the workforce in the second quarter of 2012 and potential further actions at its Budapest, Hungary operation.
As a result of shifting market preferences related to the preferred co-localization of integrated drug discovery activities, which have impacted demand for the Company’s service at this facility, AMRI is considering closing its operations in Hungary and transitioning many of the services offered at the site into other AMRI global locations, including Singapore and Hyderabad, India.
Current customer programs at AMRI Hungary may also benefit from this global integration. Any such restructuring could affect up to approximately 100 employees at the Budapest location.
The Company is commencing consultation with employee representatives to consider ways of avoiding or reducing the number of proposed redundancies, and mitigating the consequences of the redundancies.
The Company anticipates providing additional detail regarding these proposed actions in approximately one month or in conjunction with the Company’s year-end 2011 financial results.
The contemplated actions further demonstrate AMRI’s commitment to taking the necessary actions to reassess its global footprint and strengthen its core contract research and manufacturing business by focusing its resources to improve efficiency and respond to the demands of the marketplace.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018